Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Director | June 30, 2021 | July 01, 2021 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 07, 2026 | January 08, 2026 |
| Royalty Pharma plcRPRX · Entity 3100 | Director | September 30, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kaleido Biosciences, Inc.
Report date June 30, 2021 · Filed July 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.44 · Expires 2031-06-29 | Direct | 15,000 |
Reported balance
After 2021-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-30 · Grant · Acquired 15,000 · Balance 15,000 |
REGENERON PHARMACEUTICALS, INC.
Report date January 07, 2026 · Filed January 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,703 |
Ending reported balance
After 2026-01-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-07 · Exercise / conversion · Acquired 1,500 · Balance 3,203 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. Row 2 · 2026-01-07 · Sale · Disposed 1,500 · Balance 1,703 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. F2: Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $374.12 · Expires 2030-01-02 | Direct | 2,861 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Exercise / conversion · Disposed 1,500 · Balance 2,861 F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. F3: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025.
F2: Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price.
F3: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
Royalty Pharma plc
Report date September 30, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary SharesSEC Table I · non-derivative | Direct | 79,823 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 642 · Balance 79,823 F1: Reflects Class A Ordinary Shares issued to the Reporting Person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects Class A Ordinary Shares issued to the Reporting Person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cidara Therapeutics, Inc.
Report date January 07, 2026 · Filed January 08, 2026
Section 16 reporting ended · disclosed 2026-01-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Disposition to issuer · Disposed 15 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes. F4: The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.20 · Expires 2031-01-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Disposition to issuer · Disposed 1,750 · Balance 0 F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.40 · Expires 2031-06-22 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-07 · Disposition to issuer · Disposed 875 · Balance 0 F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.60 · Expires 2032-06-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-07 · Disposition to issuer · Disposed 1,400 · Balance 0 F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.40 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-07 · Disposition to issuer · Disposed 2,125 · Balance 0 F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2034-07-17 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-07 · Disposition to issuer · Disposed 2,125 · Balance 0 F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.81 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-07 · Disposition to issuer · Disposed 16,000 · Balance 0 F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.31 · Expires 2035-06-17 | Direct | 0 |
Reported balance
After 2026-01-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-07 · Disposition to issuer · Disposed 11,100 · Balance 0 F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2]
F2: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3]
F3: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes.
F4: The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
F5: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024.
F6: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 30, 2026 Filed Oct 1, 2026 00:33 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 642 | $58.41 | $37,496.33 |
DisclosureSEC source: 0001683607-26-000016 · wk-form4_1790800401.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,823 F1 · price: Reflects Class A Ordinary Shares issued to the Reporting Person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 30, 2026 Filed Jun 30, 2026 21:15 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 689 | $54.40 | $37,481.46 |
DisclosureSEC source: 0001683607-26-000014 · wk-form4_1782854114.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,181 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:20 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 4,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001683607-26-000012 · wk-form4_1780950015.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,492 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 20:09 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 815 | $45.98 | $37,471.26 |
DisclosureSEC source: 0001683607-26-000010 · wk-form4_1774987765.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,947 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerStock Option (right to buy) · Derivative | 11,100 | Not disclosed Strike: $21.31 | Not disclosed |
DisclosureSEC source: 0001683607-26-000006 · wk-form4_1767835143.xml · derivative · entry 8 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,100 shares Expires 2035-06-17 F6 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. F6 · derivative.exercise_date: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerStock Option (right to buy) · Derivative | 16,000 | Not disclosed Strike: $22.81 | Not disclosed |
DisclosureSEC source: 0001683607-26-000006 · wk-form4_1767835143.xml · derivative · entry 7 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,000 shares Expires 2034-12-16 F6 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. F6 · derivative.exercise_date: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerStock Option (right to buy) · Derivative | 2,125 | Not disclosed Strike: $12.64 | Not disclosed |
DisclosureSEC source: 0001683607-26-000006 · wk-form4_1767835143.xml · derivative · entry 6 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,125 shares Expires 2034-07-17 F6 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. F6 · derivative.exercise_date: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerStock Option (right to buy) · Derivative | 2,125 | Not disclosed Strike: $23.40 | Not disclosed |
DisclosureSEC source: 0001683607-26-000006 · wk-form4_1767835143.xml · derivative · entry 5 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,125 shares Expires 2033-06-21 F5 · derivative.exercise_price: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5 · shares: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. F6 · derivative.exercise_date: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerStock Option (right to buy) · Derivative | 1,400 | Not disclosed Strike: $10.60 | Not disclosed |
DisclosureSEC source: 0001683607-26-000006 · wk-form4_1767835143.xml · derivative · entry 4 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,400 shares Expires 2032-06-21 F5 · derivative.exercise_price: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5 · shares: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. F6 · derivative.exercise_date: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerStock Option (right to buy) · Derivative | 875 | Not disclosed Strike: $38.40 | Not disclosed |
DisclosureSEC source: 0001683607-26-000006 · wk-form4_1767835143.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 875 shares Expires 2031-06-22 F5 · derivative.exercise_price: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5 · shares: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. F6 · derivative.exercise_date: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerStock Option (right to buy) · Derivative | 1,750 | Not disclosed Strike: $50.20 | Not disclosed |
DisclosureSEC source: 0001683607-26-000006 · wk-form4_1767835143.xml · derivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires 2031-01-21 F5 · derivative.exercise_price: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F5 · shares: The exercise price and the number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. F6 · price: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. F6 · derivative.exercise_date: As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 01:19 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | Disposition to issuerCommon Stock | 15 | $221.50 | $3,322.50 |
DisclosureSEC source: 0001683607-26-000006 · wk-form4_1767835143.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] F2 · kind: [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] F3 · kind: [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes. F4 · shares: The number of securities reported herein have been adjusted to reflect the 1-for-20 reverse stock split effected by the Issuer on April 24, 2024. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $374.12 | $0.00 |
DisclosureSEC source: 0001683607-26-000008 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,861 Underlying: Common Stock · 1,500 shares Expires 2030-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. F3 · derivative.exercise_date: On the date of the Company's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,500 | $800.00 | $1,200,000.00 |
DisclosureSEC source: 0001683607-26-000008 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,703 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. F2 · price: Represents volume-weighted average price of sales of 1,500 shares of Company stock on January 7, 2026 at prices ranging from $800.00 to $800.01. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 7, 2026 at each separate price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 21:03 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,500 | $374.12 | $561,180.00 |
DisclosureSEC source: 0001683607-26-000008 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001683607-26-000004 · edgardoc.xml · derivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001683607-26-000004 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,703 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2025 Filed Jan 2, 2026 21:06 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 967 | $38.74 | $37,463.32 |
DisclosureSEC source: 0001683607-26-000002 · wk-form4_1767388000.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,132 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 760 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001683607-25-000006 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 756 Underlying: Common Stock · 760 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 760 | $750.00 | $570,000.00 |
DisclosureSEC source: 0001683607-25-000006 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,548 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 760 | $371.40 | $282,264.00 |
DisclosureSEC source: 0001683607-25-000006 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 2, 2025. Read SEC document |
| September 30, 2025 Filed Sep 30, 2025 20:54 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,047 | $35.79 | $37,469.20 |
DisclosureSEC source: 0001683607-25-000004 · wk-form4_1759265653.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,165 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 30, 2025 Filed Jun 30, 2025 21:04 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,064 | $35.24 | $37,494.83 |
DisclosureSEC source: 0001802768-25-000075 · wk-form4_1751317462.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,118 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 18, 2025 Filed Jun 18, 2025 21:03 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantStock Option (right to buy) · Derivative | 11,100 | $0.00 Strike: $21.31 | $0.00 |
DisclosureSEC source: 0001610618-25-000062 · wk-form4_1750280597.xml · derivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,100 Underlying: Common Stock · 11,100 shares Expires 2035-06-17 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) June 18, 2026 or (ii) the day prior to the date of the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| May 13, 2025 Filed May 14, 2025 21:04 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 7,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-25-000045 · wk-form4_1747256688.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,054 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 21:46 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,141 | $32.87 | $37,499.88 |
DisclosureSEC source: 0001802768-25-000017 · wk-form4_1743543999.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,440 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000002 · edgardoc.xml · derivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000002 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,548 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| December 31, 2024 Filed Jan 2, 2025 21:29 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,503 | $24.94 | $37,487.22 |
DisclosureSEC source: 0001802768-25-000006 · wk-form4_1735853350.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,299 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 23:17 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $22.81 | $0.00 |
DisclosureSEC source: 0001610618-24-000150 · wk-form4_1734650227.xml · derivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2034-12-16 F1 · derivative.exercise_date: The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of December 17, 2024. Read SEC document |
| September 30, 2024 Filed Sep 30, 2024 21:08 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,342 | $27.92 | $37,475.22 |
DisclosureSEC source: 0001802768-24-000055 · wk-form4_1727730521.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,796 F1 · price: 1. Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 756 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001968202-24-000123 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,516 Underlying: Common Stock · 756 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 756 | $1,170.00 | $884,520.00 |
DisclosureSEC source: 0001968202-24-000123 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 756 | $371.40 | $280,778.40 |
DisclosureSEC source: 0001968202-24-000123 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 756 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001883850-24-000041 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,272 Underlying: Common Stock · 756 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 756 | $1,115.00 | $842,940.00 |
DisclosureSEC source: 0001883850-24-000041 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 756 | $371.40 | $280,778.40 |
DisclosureSEC source: 0001883850-24-000041 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. Read SEC document |
| July 18, 2024 Filed Jul 19, 2024 20:55 UTC | Cidara Therapeutics, Inc. CDTX · Entity 69639 | GrantStock Option (right to buy) · Derivative | 2,125 | $0.00 Strike: $12.64 | $0.00 |
DisclosureSEC source: 0001610618-24-000106 · wk-form4_1721422504.xml · derivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,125 Underlying: Common Stock · 2,125 shares Expires 2034-07-17 F1 · derivative.exercise_date: The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 21:09 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,399 | $26.80 | $37,492.92 |
DisclosureSEC source: 0001802768-24-000040 · wk-form4_1719608984.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,454 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 756 | $0.00 Strike: $371.40 | $0.00 |
DisclosureSEC source: 0001883850-24-000037 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,028 Underlying: Common Stock · 756 shares Expires 2029-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 756 | $1,062.00 | $802,872.00 |
DisclosureSEC source: 0001883850-24-000037 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 20:41 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 756 | $371.40 | $280,778.40 |
DisclosureSEC source: 0001883850-24-000037 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,138 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:09 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 9,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001802768-24-000025 · wk-form4_1718050174.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,055 F1 · shares: Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 827 | $0.00 Strike: $380.95 | $0.00 |
DisclosureSEC source: 0001883850-24-000027 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 827 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. F2 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 827 | $1,011.00 | $836,097.00 |
DisclosureSEC source: 0001883850-24-000027 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,382 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:06 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 827 | $380.95 | $315,045.65 |
DisclosureSEC source: 0001883850-24-000027 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 27, 2024. Read SEC document |
| March 28, 2024 Filed Apr 2, 2024 21:28 UTC | Royalty Pharma plc RPRX · Entity 3100 | GrantClass A Ordinary Shares | 1,240 | $30.23 | $37,483.09 |
DisclosureSEC source: 0001802768-24-000016 · wk-form4_1712093313.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,762 F1 · price: Reflects Class A Ordinary Shares issued to the reporting person under the Issuer's 2020 Independent Director Equity Incentive Plan in lieu of a quarterly retainer payment of $37,500. Read SEC document |
| February 26, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 854 | $0.00 Strike: $391.92 | $0.00 |
DisclosureSEC source: 0001968202-24-000074 · edgardoc.xml · derivative · entry 3 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 854 shares Expires 2026-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant. Read SEC document |
| February 26, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 854 | $979.25 | $836,279.50 |
DisclosureSEC source: 0001968202-24-000074 · edgardoc.xml · nonDerivative · entry 2 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,382 Read SEC document |
| February 26, 2024 Filed Feb 26, 2024 21:07 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 854 | $391.92 | $334,699.68 |
DisclosureSEC source: 0001968202-24-000074 · edgardoc.xml · nonDerivative · entry 1 Bassler Bonnie L · CIK 0001683607 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.